Borderline ovarian tumors – literature review

Borderline ovarian tumors (BLOTs), also called semi-malignant ovarian tumors, despite a clear classification, represent one of the most controversial topics in oncogynecology. Although it is not a rare diagnosis, there are no prospective randomized studies showing clear recommendations regarding the management of this disease. The disease incidence reaches its peak when women attain their reproductive age, thus, a fertility sparing approach is often the goal of the treatment. Surgery remains the main therapeutic strategy.A clear definition for lowor high-risk patients requiring more or less aggressive treatment is lacking. Nowadays, the main factors deciding the range of therapeutic approach depends upon the histopathological features; particularly the presence of invasive implants and microinvasion, as well as the staging of the disease. Recent genetic assessment has brought new knowledge, but the extrapolation to clinical practice is still missing.

Borderline ovarian tumor; Peritoneal implants; Fertility sparing surgery; Invasive implants.

[1] Shin Y.J., Kim J.Y., Lee H.J., Park J.Y., Nam J.H.: “Paratubal serous borderline tumor”. J. Gynecol. Oncol., 2011, 22, 295.

[2] Pickel H., Tamussino K.: “History of Gynecological Pathology: XIV. Hermann Johannes Pfannenstiel“. Int. J. Gynecol. Pathol., 2003, 22, 310.

[3] Abel C., Bandler S.W.: “A Manual of Microscopic Technique and Diagnosis in Gynecological Practice For Students and Physicians”. Gynecological Pathology. New York: William Wood & Company, 1901.

[4] Taylor H.C. Jr.: “Malignant and semi-malignant tumors of the ovary”. Surg. Gynecol. Obstet., 1929, 48, 204.

[5] Fisher E.R., Krieger J.S., Skirpan P.J.: “Ovarian cystoma. Clinicopathological observations”. Cancer, 1955, 8, 437.

[6] FIGO. International Federation of Gynecology and Obstetrics.: “Classification and staging of malignant tumours in the female pelvis”. Acta Obstet. Gynecol. Scand., 1971, 50, 1.

[7] Serov S.F., Scully R.E., Sobin L.H.: “International Histologic Classification of Tumours. No. 9. Histological Typing of Ovarian Tumours”. Geneva: World Health Oragnization, 1973.

[8] Leitao M.M. Jr., Boyd J., Hummer A., Olvera N., Arroyo C.D., Venkatraman E., et al.: “Clinicopathologic analysis of early-stage sporadic ovarian carcinoma“. Am. J. Surg. Pathol., 2004, 28, 147.

[9] Skírnisdóttir I., Garmo H., Wilander E., Holmberg L.: “Borderline ovarian tumors in Sweden 1960-2005: trends in incidence and age at diagnosis compared to ovarian cancer”. Int. J. Cancer, 2008, 123, 1897.

[10] Bjørge T., Engeland A., Hansen S., Tropé C.G.: “Trends in the incidence of ovarian cancer and borderline tumours in Norway, 1954- 1993”. Int. J. Cancer, 1997, 71, 780.

[11] Fauvet R., Brzakowski M., Morice P., Resch B., Marret H., Graesslin O., Darai E.: “Borderline ovarian tumors diagnosed during pregnancy exhibit a high incidence of aggressive features: results of a French multicenter study”. Ann. Oncol., 2012, 23, 1481.

[12] Bent C.L., Sahdev A., Rockall A.G., Singh N., Sohaib S.A., Reznek R.H.: “MRI appearances of borderline ovarian tumours”. Clin. Radiol., 2009, 64, 430.

[13] Riopel M.A., Ronnett B.M., Kurman R.J.: “Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors: Atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas”. Am. J. Surg. Pathol., 1999, 23, 617.

[14] Lu C., Bonome T., Li Y.: “Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma”. Cancer Res., 2007, 67, 1757.

[15] Katzenstein A.L., Mazur M.T., Morgan T.E., Kao M.S.: “Proliferative serous tumors of the ovary: histologic features and prognosis”. Am. J. Surg. Pathol., 1978, 2, 339.

[16] Kennedy A.W., Hart W.R.: “Ovarian papillary serous tumors of low malignant potential (serous borderline tumors): a long term followup study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma”. Cancer, 1996, 78, 278.

[17] Scully R.E., Young R.H., Clement P.B.: “Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament”. In: Rosai J. (ed). Atlas of Tumor Pathology, Third Series, Fascicle 23. Washington, DC: Armed Forces Institute of Pathology, 1998.

[18] Segal G.H., Hart W.R.: “Ovarian serous tumors of low malignant potential (serous borderline tumors): the relationship of exophytic surface tumor to peritoneal ´implants´”. Am. J. Surg. Pathol., 1992, 16, 557.

[19] Prat J., de Nictolis M.: “Serous borderline tumors of the ovary: a long-term follow up study of 137 cases, including 18 with micropapillary pattern and 20 with microinvasion”. Am. J. Surg. Pathol., 2002, 26, 1111.

[20] Deavers M.T., Gershenson D.M., Tortolero-Luna G., Malpica A., Lu K.H., Silva E.G.: “Micropapillary and cribriform patterns in ovarian serous tumors of low malignant potential: a study of 99 advanced stage cases”. Am. J. Surg. Pathol., 2002, 26, 1129.

[21] Slomovitz B.M., Caputo T.A., Gretz III H.F., Economos K., Tortoriello D.V., Schlosshauer P.W., et al.: “A comparative analysis of 57 serous borderline tumors with or without a noninvasive micropapillary component”. Am. J. Surg. Pathol., 2002, 26, 592.

[22] Lee K.R., Scully R.E.: “Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with ´pseudomyxoma peritonei´”. Am. J. Surg. Pathol., 2000, 24, 1447.

[23] Rodriguez I.M., Prat J.: “Mucinous tumors of the ovary: a clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas”. Am. J. Surg. Pathol., 2002, 26, 139.

[24] Kennedy A.W., Hart W.R.: “Ovarian papillary serous tumors of low malignant potential (serous borderline tumors): a long term followup study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma”. Cancer, 1996, 78, 278.

[25] Bell D.A., Scully R.E.: “Ovarian serous borderline tumors with microinvasion: a report of 21 cases”. Hum. Pathol., 1990, 21, 397.

[26] Hanselaar A.G., Vooijs G.P., Mayall B., Ras-Zeijlmans G.J., Chadha- Ajwani S.: “Epithelial markers to detect occult microinvasion in serous ovarian tumors”. Int. J. Gynecol. Pathol., 1993, 12, 20.

[27] McKenney J.K., Balzer B.L., Longacre T.A.: “Ovarian serous tumors of low malignant potential with stromal microinvasion: a clinicopathologic study of 36 cases”. Mod. Pathol., 2004, 14, 205.

[28] Gilks C.B., Alkushi A., Yue J.J., Lanvin D., Ehlen T.G., Miller D.M.: “Advanced-stage serous borderline tumors of the ovary: a clinicopathological study of 49 cases”. Int. J. Gynecol. Pathol., 2002, 22, 29.

[29] Bell D.A., Scully R.E.: “Serous borderline tumors of the peritoneum”. Am. J. Surg. Pathol., 1990, 14, 230.

[30] Biscotti C.V., Hart W.R.: “Peritoneal serous micropapillomatosis of low malignant potential (serous borderline tumors of the peritoneum): a clinicopathologic study of 17 cases”. Am. J. Surg. Pathol., 1992, 16, 467.

[31] Zanotti K.M., Hart W.R., Kennedy A.W., Belinson J.L., Casey G.: “Allellic imbalance on chromosome 17p13 in borderline (low malignant potential) epithelial ovarian tumors”. Int. J. Gynecol. Pathol. 1999, 18, 247.

[32] Diebold J., Seemuller F., Lohrs U.: “K-RAS mutations in ovarian and extraovarian lesions of serous tumors of borderline malignancy”. Lab. Invest., 2003, 83, 251.

[33] Silva E.G., Tornos C., Zhuang Z., Merino M.J., Gershenson D.M.: “Tumor recurrence in stage I ovarian serous neoplasms of low malignant potential”. Int. J. Gynecol. Pathol., 1998, 17, 1.

[34] Koern J., Trope C.G., Abeler V.M.: “A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970-1982: a review of clinicopathologic features and treatment modalities”. Cancer, 1993, 71, 1810.

[35] Bell D.A., Weinstock M.A., Scully R.E.: “Peritoneal implants of ovarian serous borderline tumors: histologic features and prognosis”. Cancer, 1988, 62, 2212.

[36] Barnhill D.R., Kurman R.J., Brady M.F., Omura G.A., Yordan E., Given F.T., et al.: “Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential: a Gynecologic Oncology Group study”. J. Clin. Oncol., 1995, 13, 2752.

[37] Shih K.K., Garg K., Soslow R.A., Chi D.S., Abu-Rustum N.R., Barakat R.R.: “Accuracy of frozen section diagnosis of ovarian borderline tumor”. Gynecol. Oncol., 2011, 123, 517.

[38] Gershenson D.M., Silva E.G., Levy L., Burke T.W., Wolf J.K., Tornos C.: “Ovarian serous borderline tumors with invasive peritoneal implants”. Cancer, 1998, 82, 1096.

[39] Rutgers J.L., Scully R.E.: “Ovarian mullerian mucinous papillary cystadenomas of borderline malignancy: a clinicopathologic analysis”. Cancer. 1988, 61, 340.

[40] Hart W.R., Norris H.J.: “Borderline and malignant mucinous tumors of the ovary. Histologic criteria and clinical behavior”. Cancer, 1973, 31, 1031.

[41] Nayar R., Siriaunkgul S., Robbins K.M., McGowan L., Ginzan S., Silverberg S.G.: “Microinvasion in low malignant potential tumors of the ovary”. Hum. Pathol., 1996, 27, 521.

[42] Kliman L., Rome R.M., Fortune D.W.: “Low malignant potential tumors of the ovary: a study of 76 cases”. Obstet. Gynecol., 1986, 68, 338.

[43] Ronnett B.M., Zahn C.M., Kurman R.J., Kass M.E., Sugarbaker P.H., Shmookler B.M.: “Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis: A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to “pseudomyxoma peritonei”. Am. J. Surg. Pathol., 1995, 19, 1390.

[44] Prayson R.A., Hart W.R., Petras R.E.: “Pseudomyxoma peritonei: A clinicopathologic study of 19 cases with emphasis on site of origin and nature of associated ovarian tumors”. Am. J. Surg. Pathol., 1994, 18, 591.

[45] Hoerl H.D., Hart W.R.: “Primary ovarian mucinous cystadenocarcinomas: a clinicopathologic study of 49 cases with long-term followup”. Am. J. Surg. Pathol., 1998, 22, 1449.